Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to promote weight loss. But if you’re still hungry on semaglutide ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with ...

Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk Sunday, June 22 at 4:30 - 6:00 PM CT About the ADA's Scientific Sessions The ADA's ...

In Australia, semaglutide is not on the Pharmaceutical Benefits Scheme (PBS) for weight loss. "People with schizophrenia urgently need access to effective treatments for obesity, such as ...

Eight individuals, including employees from Dr Reddy's Lab, have been arrested for stealing Semaglutide powder worth over Rs. 2 crore. The theft was discovered in a warehouse in Srikakulam ...

CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including ...

GLP-1 drugs, such as semaglutide (sold under brand names like Ozempic and Wegovy), are a class of medications that mimic a hormone called glucagon-like peptide-1 (GLP-1).

Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their risk of developing neovascular age-related macular degeneration (nAMD ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

EMA’s safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic ...

You can take semaglutide for weight loss indefinitely. There’s no set cut-off time, as the drug was originally designed as a diabetes medication and intended for long-term use.

AUSTIN, Texas, June 12, 2025--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that ...